Comment from Flagship Pioneering

Summary: Flagship Pioneering, a biotechnology company, supports the FDA's draft guidance but urges the Agency to balance patient safety with the need to foster innovation by avoiding overregulation. They recommend narrowing the scope of oversight to AI applications that directly impact patient safety, providing clearer risk-based requirements, and establishing a centralized AI council to facilitate early engagement with developers.